Securities Registration: Employee Benefit Plan (s-8)
March 08 2018 - 5:05PM
Edgar (US Regulatory)
As filed with the U.S. Securities and Exchange Commission on March 8, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Calithera Biosciences, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
|
|
27-2366329
|
(State or other jurisdiction of
Incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
343 Oyster Point Blvd., Suite 200
South San Francisco, California 94080
(Address of principal executive offices) (Zip code)
Calithera Biosciences, Inc. 2014 Equity Incentive Plan
Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan
Calithera Biosciences, Inc. 2018 Inducement Plan
(Full title of the plans)
Susan M. Molineaux, Ph.D.
President and Chief Executive Officer
343 Oyster Point Blvd., Suite 200
South San Francisco, California 94080
(650)
870-1000
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
Barbara A.
Kosacz
John T. McKenna
Seth J. Gottlieb
Cooley
LLP
3175 Hanover Street
Palo Alto, California 94304
(650)
843-5000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule
12b-2
of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☒
|
|
|
|
|
Non-accelerated
filer
|
|
☐ (Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
☐
|
|
|
|
|
Emerging growth company
|
|
☒
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities
to be Registered
|
|
Amount to be
Registered(1)
|
|
Proposed
Maximum
Offering Price
per Share(3)
|
|
Proposed
Maximum
Aggregate
Offering Price(3)
|
|
Amount of
Registration Fee
|
Common Stock, par value $0.0001 per share
|
|
|
|
|
|
|
|
|
2014 Equity Incentive Plan
|
|
1,430,373(2)
|
|
$7.775
|
|
$11,121,150.08
|
|
$1,384.59
|
2014 Employee Stock Purchase Plan
|
|
250,000(2)
|
|
$7.775
|
|
$1,943,750.00
|
|
$242.00
|
2018 Inducement Plan
|
|
1,000,000
|
|
$7.775
|
|
$7,775,000.00
|
|
$967.99
|
Total
|
|
2,680,373
|
|
|
|
$20,839,900.08
|
|
$2,594.58
|
|
|
(1)
|
Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of Calithera Biosciences, Inc. that become issuable under the 2014
Equity Incentive Plan, the 2014 Employee Stock Purchase Plan and the 2018 Inducement Plan set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the
number of outstanding shares of the Registrants common stock.
|
(2)
|
Represents additional shares of the Registrants common stock reserved for future issuance under the 2014 Equity Incentive Plan and the 2014 Employee Stock Purchase Plan by reason of the automatic increase
provisions therein.
|
(3)
|
Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $7.775, the average of the high and low prices of the
Registrants common stock as reported on The NASDAQ Global Market on March 1, 2018.
|
EXPLANATORY NOTE
Calithera Biosciences, Inc. (the
Registrant
) is filing this Registration Statement on
Form S-8
for the purpose of registering an additional (a) 1,430,373 shares of its common stock, par value $0.0001 per share (the
Common Stock
), issuable to eligible persons
under the 2014 Equity Incentive Plan and 250,000 shares of its Common Stock, issuable to eligible persons under the 2014 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the
Registrants registration statements on
Form S-8
filed on (i) October 2, 2014 (File
No. 333-199126),
(ii) May 11, 2015 (File
No. 333-204056),
(iii) March 15, 2016 (File
No. 333-210193)
and (iv) March 16, 2017 (File
No. 333-216740)
(collectively, the
Prior Forms
S-8
) and (b) 1,000,000 shares of Common Stock issuable to eligible persons under the 2018 Inducement Plan, which Common Stock is in addition to the
shares of Common Stock registered on the Prior Forms
S-8.
PART II
ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
Pursuant to General Instruction E to Form
S-8,
the contents of the Prior Forms
S-8
are incorporated by reference herein.
All other reports and documents subsequently filed by the
Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form
8-K
and exhibits furnished on such form that relate to
such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then
remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by
reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 8. EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe
that it meets all of the requirements for filing on Form
S-8
and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of South San
Francisco, State of California, on March 8, 2018.
|
|
|
Calithera Biosciences, Inc.
|
|
|
By:
|
|
/s/ Susan M. Molineaux
|
|
|
Susan M. Molineaux, Ph.D.
|
|
|
President and Chief Executive Officer
|
POWER OF ATTORNEY
K
NOW
A
LL
P
ERSONS
B
Y
T
HESE
P
RESENTS
, that each person whose signature appears below constitutes and appoints Susan M. Molineaux, Ph.D. and Stephanie Wong, and each or any one of them, his or her true and lawful
attorney-in-fact
and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all
amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
attorneys-in-fact
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection
therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
attorneys-in-fact
and agents, or
any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the
requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
/s/ Susan M. Molineaux
Susan M. Molineaux, Ph.D.
|
|
President, Chief Executive Officer and Director
(Principal Executive Officer and Principal
Financial Officer)
|
|
March 8, 2018
|
|
|
|
/s/ Stephanie Wong
Stephanie Wong
|
|
Senior Vice President, Finance and Secretary
(Principal Accounting Officer)
|
|
March 8, 2018
|
|
|
|
/s/ Sunil Agarwal
Sunil Agarwal, M.D.
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ Jonathan G. Drachman
Jonathan G. Drachman, M.D.
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ Jean M. George
Jean M. George
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ Suzy Jones
Suzy Jones
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ Deepa R. Pakianathan
Deepa R. Pakianathan, Ph.D.
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ Blake Wise
Blake Wise
|
|
Director
|
|
March 8, 2018
|
|
|
|
/s/ H. Ward Wolff
H. Ward Wolff
|
|
Director
|
|
March 8, 2018
|
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024